Onegene Biotechnology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Onegene Biotechnology - overview
Established
2016
Location
Suwon, -, South Korea
Primary Industry
Biotechnology
About
Based in South Korea, and founded in 2016, Onegene Biotechnology provides therapeutics that help in the treatment of chronic diseases. As of 2023, the company is headed by its CEO Dr. Sungjin Park. In May 2022, investors BNH Investments, Devsisters Ventures, ESV Investments, Korea Investment & Securities, Medici Investments, Premier Partners, Quantum Ventures Korea, Shinhan Venture Investment, Solid's Investments, Stick Ventures, Time Folio Asset Management, and UTC Investments raised KRW 40.
7 billion in series B funding. The company offers multi-targeting tri-or tetra-specific protein-based drugs which are developed by using different therapeutic modalities and it is helpful in the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, and cancers. The firm protein-binding platform technology (UniStac) removes the heterodimerization engineering process and uses Enzyme-mediated protein-protein conjugation technology which helps in the treatment of complex and chronic diseases.
Current Investors
UTC Investment, Premier Partners, SJ Investment Partners
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.onegenebt.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Onegene Biotechnology - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | 1,050,000 | - | - | - | - |
| % Revenue Growth (YoY) | - | (100.0%) | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | (1,098,133,000) | (5,353,635,000) | - | - | - |
| Operating Margin | (104584.1%) | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (1,016,877,000) | (4,972,469,000) | - | - | - |
| % Net Margin | (96845.4%) | - | - | - | - |
Onegene Biotechnology - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B | Completed | Onegene Biotechnology | - | ||||||||
| Series A | Completed | Onegene Biotechnology | - | ||||||||
| Seed | Completed | Onegene Biotechnology | - |
Displaying 1 - 3 of 3
Onegene Biotechnology - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.